Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer

Authors:

Abstract
Colorectal cancer is the second leading cause of cancer-related mortality in the US, with the country’s second-highest annual cost of $14.1 billion in 2010.1 Costs were projected to reach $17.4 billion in 2020.1 Standard of care in the management of locally advanced rectal cancer usually entails neoadjuvant long-course chemoradiotherapy (LCCRT) for 5 to 6 weeks,2,3 followed by total mesorectal excision (TME).4,5 Although this treatment strategy has led to decreased local recurrence rates of 4% to 9%,5-7 distant metastases remain the predominant site of recurrence,8 and the management of metastatic rectal cancer incurs significant cost and morbidity.9

This publication has 54 references indexed in Scilit: